Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo do reparo de tecidos na doença inflamatória intestinal que explora a tecnologia orgânica (ORGANOIDS)

18 de setembro de 2026 atualizado por: Assistance Publique Hopitaux De Marseille

Inflammatory Bowel Diseases (IBD) are chronic inflammations of the gastrointestinal tract. Regardless of the etiology, a common trait of IBD pathogenesis is the inflammatory damage inflicted on the intestinal mucosa and the loss of intestinal epithelial barrier integrity. Therefore, understanding the mechanisms that govern IEC's capacity to maintain barrier function and to orchestrate mucosal healing is considered a major goal in translational research. The investigators are interested in understanding how the inflammatory environment present in the intestinal mucosa, of IBD patients influences epithelial cells capacity to govern repair. The complexities of the cytokine and metabolic milieu present in IBD patients render the study of the contribution of each cytokine, metabolite, and intracellular pathway extremely complicated. Therefore, most of the processes that govern tissue regeneration are studied with the use of mouse models that recapitulate one or multiple features of IBD and allow for genetical modifications of the gene and pathway of interest. While mouse models are uniquely suited to study the complex crosstalk between the immune system, the microbiota, and the intestinal epithelia, they introduce the important problem of species-specific differences, which can hamper the translational value of mouse studies.

To overcome these shortcomings, the investigators propose to explore the influence of cytokines and metabolites in digestive organoids derived from patients and controls. Importantly, it was demonstrated that gene expression and innate immune responses are altered in primary organoids derived from patients with IBD, including altered ability to proliferate, respond to cytokines, metabolic capacity, and efficiently form organoids suggesting that major differences between patient's and control's epithelial cell biology can be faithfully replicated in this system.

Given these premises, the investigators propose the following objectives:

Primary objective:

The main objective of this study is to establish that patient's epithelial cells from inflamed mucosae have decreased ability to repair the intestinal mucosa, as compared to epithelial cells from non-inflamed regions in the same patient, or to control subject with no inflammatory digestive diseases.

The investigators will explore this question both deriving organoids from clinical samples and exposing them to pro inflammatory cytokines and metabolites in vitro, as well as by analyzing repair responses from the aforementioned clinical samples ex vivo.

Secondary objective

The secondary goals of this study are:

- To compare organoids derived from: epithelia in inflamed mucosa of IBD patients, epithelia in non-inflamed mucosa of IBD patients, and epithelia from the mucosa of non-IBD controls in their capacity to mount a repair response in response to inflammatory cytokines or luminal metabolites.

Namely the investigators will evaluate the following parameters:

  • Their capacity to proliferate.
  • Their ability to survive treatment with pro-inflammatory cytokines
  • The activation of intracellular pathways associated with cell death.
  • Their overall metabolic activity.
  • The balance between stem and differentiated epithelial cell types.
  • The transcriptional activation of protective pathways such as those associated with proliferation, migration, differentiation and cell survival.
  • To evaluate hallmarks of tissue repair in biopsies derived from epithelia in inflamed mucosa of IBD patients, epithelia in non-inflamed mucosa of IBD patients, and epithelia from the mucosa of non-IBD controls, and to correlate them to the levels of inflammatory cytokines, luminal metabolites and overall disease severity. Namely the investigators will evaluate the following parameters:
  • The abundance of proliferating cells.
  • The activation of intracellular pathways associated with cell death and survival.
  • Their overall metabolic activity.
  • The balance between stem and differentiated epithelial cell types.
  • The transcriptional activation of protective pathways such as those associated with proliferation, migration, differentiation and cell survival.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

60

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

For IBD group the inclusion criteria will be:

  • Patients of either sex aged 18 years or older
  • Patient that have read the information form and signed consent
  • Patient covered with health insurance
  • Patients with Crohn's Disease or ulcerative colitis in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria, regardless of the level, severity of the disease or duration of disease progression.
  • Patients with colonic involvement of Crohn's disease or ulcerative colitis
  • Patients undergoing a screening colonoscopy in the context of IBD disease follow-up OR undergoing intestinal resection for IBD disease aggravation

For control group the inclusion criteria will be:

  • Patients of either sex aged 18 years or older
  • Patient that have read the information form and signed consent
  • Patient covered with health insurance
  • Patients undergoing a screening colonoscopy in the context of a family history of colonic neoplasia, follow-up of colonic polyps or functional intestinal disorders OR undergoing intestinal resection for intestinal neoplasia, occlusive syndrome or colostomy

The non-inclusion criteria for IBD group will be:

  • Contraindication to the anaesthetic or colonoscopy procedure
  • Patients without colonic involvement of Crohn's disease or ulcerative colitis
  • Patients of Adults without legal capacity
  • Patients in Health and Social Establishments
  • Persons in emergency situations
  • Persons deprived of their liberty
  • Non-affiliated to a social security scheme
  • Absence or refusal of the informed consent

The non-inclusion criteria for control group will be:

  • IBD disease revealed during colonoscopy or gastrointestinal resection
  • Patient suffering from Immune-Mediated Inflammatory Diseases (IMIDs)
  • Contraindication to the anaesthetic or colonoscopy procedure
  • Patients of Adults without legal capacity
  • Patients in Health and Social Establishments
  • Persons in emergency situations
  • Persons deprived of their liberty
  • Non-affiliated to a social security scheme
  • Absence or refusal of the informed consent

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Ciência básica
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Falso: Control group

Patients of either sex aged 18 years or older and undergoing a screening colonoscopy in the context of a family history of colonic neoplasia, follow-up of colonic polyps or functional intestinal disorders OR undergoing intestinal resection for intestinal neoplasia, occlusive syndrome or colostomy

Collection of 10 colonic biopsies in healthy tissue

Collection of a portion of healthy mucous membrane

Experimental: IBD group

Patients of either sex aged 18 years or older with Crohn's Disease or ulcerative colitis in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria, regardless of the level, severity of the disease or duration of disease progression or patients undergoing a screening colonoscopy in the context of IBD disease follow-up OR undergoing intestinal resection for IBD disease aggravation

Collection of a portion of healthy mucous membrane

Collection of 10 colonic biopsies in IBD inflamed tissue

Collection of a portion of IBD inflamed mucous membrane

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Repair status of IBD patient's epithelial cells from inflamed mucosae
Prazo: From enrollmet to the end of following at 1 month

To establish that patient's epithelial cells from inflamed mucosae have decreased ability to repair the intestinal mucosa, as compared to epithelial cells from non-inflamed regions in the same patient, or to control subject with no inflammatory digestive diseases

From enrollmet to the end of following at 1 month

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Evaluate the molecular mechanism involved in the reduced capacity of epithelial cells of IBD patients to repair intestinal mucosa
Prazo: From enrollment to the end of following at 1 month

Evaluation of:

  • The capacity epithelial cells of IBD patients to proliferate: ratio of Ki67+cells.
  • The ability of epithelial cells of IBD patients to survive treatment with pro-inflammatory cytokines: ratio between live and dead organoids.
  • The activation of intracellular pathways associated with cell death: relative quantification of biochemical activation of 1) apoptotic caspases,2) pyroptosis effectors (GSDMs),3) Necroptosis effectors (MLKL).
  • The balance between stem and differentiated epithelial cell types: the relative gene expression of the stemness associated genes LGR5, OLFM4, and the hallmark genes of differentiated cell types AQP8, MUC2, LYZ1, CHGA).
From enrollment to the end of following at 1 month
Genetically determine the involvement of cell death and protective pathways that reduce repair capacity in patients.
Prazo: From enrollment to the end of following at 1 month

After a genetically modify with CRISPR-CAS9 technology:

  • The capacity of modified epithelial cells of IBD patients to proliferate: ratio of Ki67+cells.
  • The ability of modified epithelial cells of IBD patients to survive treatment with pro-inflammatory cytokines: ratio between live and dead organoids.
  • The activation of intracellular pathways associated with cell death: relative quantification of biochemical activation of 1) apoptotic caspases,2) pyroptosis effectors (GSDMs),3) Necroptosis effectors (MLKL).
  • The balance between stem and differentiated epithelial cell types: the relative gene expression of the stemness associated genes LGR5, OLFM4, and the hallmark genes of differentiated cell types AQP8, MUC2, LYZ1, CHGA).
From enrollment to the end of following at 1 month
3. Explore the activation of molecular mechanisms identified in patient biopsies and correlate them with the inflammatory environment present in the patient's tissues
Prazo: From enrollment to the end of following at 1 month
  • Proliferation in FFPE biopsies and RNA from RNAlater fixed biopsies: Ki67 upregulation by immunohistochemistry (IHC), PCNA gene expression, Proliferation transcriptional signature by RNAseq etc…).
  • Cell death by biochemical analysis of cell death pathways by Western Blot (WB) and IHC in flash frozen biopsies: relative quantification of biochemical activation of 1) apoptotic caspases; 2) pyroptosis effectors (GSDMs); 3) Necroptosis effectors (MLKL).
  • Differentiation status of epithelial cells from DMSO conserved biopsies: staining of cell type markers by IHC, scRNAseq of dissociated epithelial cells.
  • The metabolic landscape of epithelial cells in flash frozen biopsies: the metabolome of the cells.
From enrollment to the end of following at 1 month

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

24 de julho de 2025

Conclusão Primária (Estimado)

24 de março de 2027

Conclusão do estudo (Estimado)

24 de março de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

28 de janeiro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

28 de janeiro de 2025

Primeira postagem (Real)

3 de fevereiro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

21 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

18 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • RCAPHM24_0062
  • 2024-A00510-47 (Outro identificador: EUdraCT)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .